Skip to main content

Table 5 Factors associated with long-term virologic response

From: Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients

Factors Univariate analysis Multivariate analysis
RR 95% CI P RR 95% CI P
Age (years) 1.007 0.995–1.018 0.262    
Sex (female/male) 1.009 0.747–1.363 0.952    
HBeAg-positive (−/+) 3.031 2.209–4.158 <0.001 1.834 1.246–2.698 0.002
Disease status (LC/CHB) 1.577 1.172–2.121 0.003 1.028 0.748–1.411 0.867
MELD (<7/≥7) 0.923 0.676–1.260 0.613    
INR 1.020 0.469–2.218 0.961    
Serum ALT (IU/L) 1.000 1.000–1.000 0.890    
Serum total bilirubin (mg/dL) 1.005 0.918–1.101 0.908    
Serum albumin (g/dL) 1.077 0.824–1.406 0.588    
IVR-3 (+/−) 4.851 2.902–8.109 <0.001 3.403 1.977–5.859 <0.001
Serum HBV DNA level
(log10 IU/mL)
0.638 0.569–0.715 <0.001 0.817 0.696–0.958 0.013
Therapy regimens (TDF/ETV) 1.162 0.868–1.555 0.313    
  1. RR relative risk, 95% CI 95% confidence interval, ALT alanine aminotransferase, CHB chronic hepatitis B, ETV entecavir, HBeAg hepatitis B e antigen, HBV hepatitis B virus, INR international normalized ratio, IVR-3 initial virologic response at 3 months, LC liver cirrhosis, MELD model for end stage liver disease, TDF tenofovir